Evidence map›Paper›PMID 27657672›Full record

ArticleChemical research in toxicology2016

Diagnostic Microdosing Approach to Study Gemcitabine Resistance.

Tiffany M Scharadin, Hongyong Zhang, Maike Zimmermann, Sisi Wang, Michael A Malfatti, George D Cimino, Kenneth Turteltaub, Ralph de Vere White, Chong-Xian Pan, Paul T Henderson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical research in toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Preclinical Models for Bladder Cancer Research.Hematology/oncology clinics of North America · 2021
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Tiffany M ScharadinDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis , Sacramento, California 95817, United States.
Hongyong ZhangDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis , Sacramento, California 95817, United States.
Maike ZimmermannDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis , Sacramento, California 95817, United States.
Sisi WangDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis , Sacramento, California 95817, United States.
Michael A MalfattiBiosciences and Biotechnology Division, Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory , Livermore, California 94550, United States.
George D CiminoAccelerated Medical Diagnostics Incorporated , Berkeley, California 95618, United States.
Kenneth TurteltaubBiosciences and Biotechnology Division, Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory , Livermore, California 94550, United States.
Ralph de Vere WhiteDepartment of Urology, University of California Davis Medical Center , Sacramento, California 95817, United States.
Chong-Xian PanDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis , Sacramento, California 95817, United States.
Paul T HendersonDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis , Sacramento, California 95817, United States.
University of California, Davis · USAccelerated Medical Diagnostics (United States) · USLawrence Livermore National Laboratory · USUniversity of California Davis Medical Center · US

Funding

Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)P41GM103483 · NIGMS · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI TURTELTAUB, KENNETH W. · 2012 to 2019
$12.0M
Training Program in Oncogenic Signals and Chromosome BiologyT32CA108459 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HEYER, WOLF-DIETRICH · 2006 to 2020
$3.6M
Characterization of Erbb Receptors in NanoparticlesR01CA155642 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI COLEMAN, MATTHEW ADRIAN, HENDERSON, PAUL THOMAS · 2011 to 2015
$1.6M
NCI NIH HHS HHSN261201000133CNCI NIH HHS HHSN261201200048CNCI NIH HHS HHSN261201200084CNCI NIH HHS R01 CA155642NCI NIH HHS T32 CA108459NIGMS NIH HHS P41 GM103483
6 · The paper itself

Abstract

Gemcitabine metabolites cause the termination of DNA replication and induction of apoptosis. We determined whether subtherapeutic "microdoses" of gemcitabine are incorporated into DNA at levels that correlate to drug cytotoxicity. A pair of nearly isogenic bladder cancer cell lines differing in resistance to several chemotherapy drugs were treated with various concentrations of

Indexed as

Antineoplastic AgentsArea Under CurveCell Line, TumorDeoxycytidineDNA RepairDose-Response Relationship, DrugGemcitabineHumansAntineoplastic AgentsDeoxycytidineGemcitabine

Identifiers

PMID27657672
PMCPMC5385140
OpenAlexW2523226757

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.